Portolano Cavallo

Life Sciences

Blog

28 May
Deblistering: current regulatory framework in light of the new opinion issued by the Council of State
In recent years, the practice of deblistering has generated significant debate, largely due to the absence of a uniform national regulatory framework.
28 May
The new tariffs regime and the new Federal Orders by the US Trump administration: first initial thoughts on certain legal and operational impacts for EU pharmaceutical business
President Trump has announced specific tariffs on pharmaceutical products within next weeks.
28 May
Pharmaceuticals and health products purchased online: the processing of user data
The processing of “health data”, given its sensitive nature, can pose significant risks to the rights and fundamental freedoms of data subjects.
28 May
Online sale of drugs: recent trends in EU case law
The promotion and online sale of medicinal products are subject to a series of regulatory provisions and constraints.
28 May
Medical device payback: The Regional Administrative Court of Lazio rejects suppliers’ appeals
In a series of rulings issued in May 2025, the Regional Administrative Court of Lazio dismissed the appeals filed by medical device suppliers challenging the payback mechanism.
28 May
Drug advertising and commercial claims: the Regional Administrative Court of Lazio validates references to format-based savings
Public advertising that emphasizes the greater economic convenience of one over-the-counter drug format over another is considered lawful.
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the Life Sciences-Healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and Venture Capital transactions.

Close
October 6, 2023
CBD products: the Administrative Court suspended until October 24 the recent Decree of the Italian Ministry of Health listing cannabidiol for oral use among narcotic drugs, due to the lack o...
October 4, 2023
The Guidelines for regulating contractual relations between universities and research institutes and private sponsors were adopted by the relevant Italian Ministries following the amendment ...
September 21, 2023
CBS products: from September 20th, compositions for oral administration of cannabidiol obtained from Cannabis sativa extracts shall be considered as narcotic drugs in Italy, as they have bee...
July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
Search by...
Search
Follow us on
Follow us on